Lund University - Recruiting 35 years to 80 years. - Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases in Smokers/Ex-Smokers Attending Primary Care - Longitudinal Study.
NCIC Clinical Trials Group - Recruiting 18 years or older. - A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma.
Kips Bay Medical, Inc. - Recruiting 21 years or older. - Post-market Study to Evaluate Post-implant Patency Rates of the eSVS Mesh in the Treatment of Saphenous Vein Graphs During Coronary Artery Bypass Grafting Versus Saphenous Vein Grafts Without the eSVS Mesh Via Coronary Angiography and Duplex Ultra-Sonography Results.
ECRI bv - Recruiting 21 years or older. - A Single-arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating.
China National Center for Cardiovascular Diseases - Recruiting 18 years or older. - The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Revascularization in Patients With Three-vessel Coronary Heart Disease.
Medical Care Center Prof. Mathey, Prof. Schofer, Ltd. - Recruiting 18 years to 75 years. - Postmarketing Surveillance Registry to Monitor Everolimus-eluting Bioresorbable Vascular Scaffold Following Rotational Atherectomy for the Treatment of Complex Coronary Lesions - The ASSURE ROT Registry.
National Cancer Institute (NCI) - Recruiting 20 years to 74 years. - An Investigational Study of Chemoradiosensitivity Prediction With Genetic Profiling of Esophageal Biopsy for Squamous Cell Carcinoma of the Esophagus.
University of Connecticut Health Center - Recruiting 18 years or older. - A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness..
Hospital Authority, Hong Kong - Recruiting 20 years to 75 years. - Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?.
Japan Clinical Oncology Group - Recruiting 21 years to 74 years. - Mesorectal Excision With Lateral Lymph Node Dissection Versus Without Lateral Lymph Node Dissection for Clinical Stage II, III Lower Rectal Cancer (JCOG0212).
Mesorectal excision with lateral lymph node dissection; Mesorectal excision without lateral lymph node excision
Japan Clinical Oncology Group - Recruiting 20 years to 75 years. - Randomized Phase III Trial of Surgery Plus Neoadjuvant TS-1 and Cisplatin Compared With Surgery Alone for Type 4 and Large Type 3 Gastric Cancer: Japan Clinical Oncology Group Study (JCOG 0501).
Gastrectomy with more than D2 dissection; Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy